Therapeutic potential of adult bone marrow‐derived mesenchymal stem cells in diseases of the skeleton
- 19 May 2010
- journal article
- review article
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 111 (2), 249-257
- https://doi.org/10.1002/jcb.22701
Abstract
Mesenchymal stem cells (MSCs) are the most popular among the adult stem cells in tissue engineering and regenerative medicine. Since their discovery and functional characterization in the late 1960s and early 1970s, MSCs or MSC‐like cells have been obtained from various mesodermal and non‐mesodermal tissues, although majority of the therapeutic applications involved bone marrow‐derived MSCs. Based on its mesenchymal origin, it was predicted earlier that MSCs only can differentiate into mesengenic lineages like bone, cartilage, fat or muscle. However, varied isolation and cell culturing methods identified subsets of MSCs in the bone marrow which not only differentiated into mesenchymal lineages, but also into ectodermal and endodermal derivatives. Although, true pluripotent status is yet to be established, MSCs have been successfully used in bone and cartilage regeneration in osteoporotic fracture and arthritis, respectively, and in the repair of cardiac tissue following myocardial infarction. Immunosuppressive properties of MSCs extend utility of MSCs to reduce complications of graft versus host disease and rheumatoid arthritis. Homing of MSCs to sites of tissue injury, including tumor, is well established. In addition to their ability in tissue regeneration, MSCs can be genetically engineered ex vivo for delivery of therapeutic molecule(s) to the sites of injury or tumorigenesis as cell therapy vehicles. MSCs tend to lose surface receptors for trafficking and have been reported to develop sarcoma in long‐term culture. In this article, we reviewed the current status of MSCs with special emphasis to therapeutic application in bone‐related diseases. J. Cell. Biochem. 111: 249–257, 2010.Keywords
This publication has 84 references indexed in Scilit:
- Mesenchymal Stem Cells Expressing Osteogenic and Angiogenic Factors Synergistically Enhance Bone Formation in a Mouse Model of Segmental Bone DefectMolecular Therapy, 2010
- The Peroxisome Proliferator-Activated Receptor-γ Agonist Rosiglitazone Increases Bone Resorption in Women with Type 2 Diabetes: A Randomized, Controlled TrialCalcified Tissue International, 2010
- Allogeneic Hematopoietic Stem-Cell Transplantation for Sickle Cell DiseaseNew England Journal of Medicine, 2009
- Therapeutic Potential of Adult Bone Marrow–Derived Mesenchymal Stem Cells in Prostate Cancer Bone MetastasisClinical Cancer Research, 2009
- Deconstructing Stem Cell Tumorigenicity: A Roadmap to Safe Regenerative MedicineThe International Journal of Cell Cloning, 2009
- A Perivascular Origin for Mesenchymal Stem Cells in Multiple Human OrgansCell Stem Cell, 2008
- Mesenchymal stem cells overexpressing interleukin-10 attenuate collagen-induced arthritis in miceClinical and Experimental Immunology, 2008
- Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part IIArthritis & Rheumatism, 2007
- Vascular endothelial growth factor can signal through platelet-derived growth factor receptorsThe Journal of cell biology, 2007
- Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statementCytotherapy, 2006